{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T11:16:02Z","timestamp":1788434162391,"version":"build-2803163510"},"reference-count":27,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Clin. Med.","JCM"],"abstract":"<jats:p>Background\/Objectives: Excess adipose tissue is associated with adverse changes in muscle metabolism and body composition. GLP-1 receptor agonists (GLP-1 RA) have transformed the treatment of obesity; however, concerns remain regarding the potential impact of treatment-associated weight loss on lean mass. This study aimed to evaluate the effects of GLP-1 RA on body composition in adults with obesity without type II diabetes mellitus (T2DM), with a particular focus on changes in lean mass. Methods: A database search of Medline Ultimate, Scopus, Web of Science, PubMed, and Embase was conducted to identify studies published up to December 30, 2024. Randomized controlled trials involving adults with obesity and without T2DM who received GLP-1 RA and reported changes in body composition were included. The protocol was registered with PROSPERO (CRD42025645378). Random-effects meta-analysis was performed using inverse-variance weighting. Results: A total of 2776 articles were identified, of which three trials comprising 171 participants met the inclusion criteria. Compared with controls, participants receiving GLP-1 RA treatment experienced greater reductions in lean mass (MD = \u22120.78 kg, 95% CI: [\u22121.37 to \u22120.16], I2 = 63.2%). GLP-1 RA treatment was also associated with a significant reduction in fat mass (MD = \u22123.43 kg, 95% CI: [\u22125.94 to \u22120.93], I2 = 78.2%). Conclusions: The loss of lean mass was greater in patients treated with GLP-1 RA than in the control group. These results highlight the importance for clinicians to incorporate lifestyle interventions, including physical activity and nutritional support, alongside therapy with GLP-1 RA.<\/jats:p>","DOI":"10.3390\/jcm15176818","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:10:33Z","timestamp":1788430233000},"page":"6818","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Impact of Glucagon-like Peptide-1 (GLP-1) Receptor Agonists on Body Composition in Individuals with Overweight and Obesity: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-5236-0699","authenticated-orcid":false,"given":"Mi\u0142osz","family":"Wo\u017aniak","sequence":"first","affiliation":[{"name":"Student Scientific Club of Lifestyle Medicine, 3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zofia","family":"Tarcz","sequence":"additional","affiliation":[{"name":"Student Scientific Club of Lifestyle Medicine, 3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Pyczek","sequence":"additional","affiliation":[{"name":"Student Scientific Club of Lifestyle Medicine, 3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Bogacka","sequence":"additional","affiliation":[{"name":"Student Scientific Club of Lifestyle Medicine, 3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9174-9356","authenticated-orcid":false,"given":"Andrzej","family":"Diniejko","sequence":"additional","affiliation":[{"name":"Student Scientific Club of Lifestyle Medicine, 3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Kury\u0142owicz","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, 00-416 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9569-1486","authenticated-orcid":false,"given":"Artur","family":"Mamcarz","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5917-8119","authenticated-orcid":false,"given":"Daniel","family":"\u015ali\u017c","sequence":"additional","affiliation":[{"name":"3rd Department of Internal Medicine and Cardiology, Medical University of Warsaw, 04-749 Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1093\/ageing\/afy169","article-title":"Sarcopenia: Revised European consensus on definition and diagnosis","volume":"48","author":"Bahat","year":"2019","journal-title":"Age Ageing"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.arr.2016.09.008","article-title":"Sarcopenic obesity or obese sarcopenia: A cross talk between age-associated adipose tissue and skeletal muscle inflammation as a main mechanism of the pathogenesis","volume":"35","author":"Kalinkovich","year":"2017","journal-title":"Ageing Res. Rev."},{"key":"ref_4","first-page":"339","article-title":"Sarcopenic obesity and weight loss-induced muscle mass loss","volume":"28","author":"Caturano","year":"2025","journal-title":"Curr. Opin. Clin. Nutr. Metab. Care"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/ggi.12579","article-title":"Association of sarcopenic obesity with the risk of all-cause mortality: A meta-analysis of prospective cohort studies","volume":"16","author":"Tian","year":"2016","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"112155","DOI":"10.1016\/j.exger.2023.112155","article-title":"The association between muscle-to-fat ratio and cardiometabolic risks: The China National Health Survey","volume":"175","author":"He","year":"2023","journal-title":"Exp. Gerontol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3422","DOI":"10.1038\/s41598-025-88167-1","article-title":"The lean body mass to visceral fat mass ratio is negatively associated with cardiometabolic disorders: A cross-sectional study","volume":"15","author":"Shao","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: A systematic analysis for the Global Burden of Disease Study 2021","volume":"402","author":"Ong","year":"2023","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1085799","DOI":"10.3389\/fendo.2023.1085799","article-title":"GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Endocrinol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s40520-015-0525-y","article-title":"Liraglutide and obesity in elderly: Efficacy in fat loss and safety in order to prevent sarcopenia. A perspective case series study","volume":"28","author":"Perna","year":"2016","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"3723","DOI":"10.2147\/DDDT.S381546","article-title":"An Effective Glucagon-Like Peptide-1 Receptor Agonists, Semaglutide, Improves Sarcopenic Obesity in Obese Mice by Modulating Skeletal Muscle Metabolism","volume":"16","author":"Ren","year":"2022","journal-title":"Drug Des. Devel Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Qu, Z., Lu, T., Shao, X., Cai, M., Dilimulati, D., Gao, X., Mao, W., Hu, F., and Su, L. (2023). Effects of a Dulaglutide plus Calorie-Restricted Diet versus a Calorie-Restricted Diet on Visceral Fat and Metabolic Profiles in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial. Nutrients, 15.","DOI":"10.3390\/nu15030556"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/ijo.2011.158","article-title":"Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide","volume":"36","author":"Astrup","year":"2012","journal-title":"Int. J. Obes."},{"key":"ref_15","unstructured":"(2026, May 23). GRADEpro GDT: GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime, 2023. Available online: https:\/\/www.gradepro.org\/."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1056\/NEJMoa2028198","article-title":"Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined","volume":"384","author":"Lundgren","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/dom.16012","article-title":"Characterizing body composition modifying effects of a glucagon-like peptide 1 receptor-based agonist: A meta-analysis","volume":"27","author":"Jiao","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"156113","DOI":"10.1016\/j.metabol.2024.156113","article-title":"Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis","volume":"164","author":"Karakasis","year":"2025","journal-title":"Metabolism"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/14656566.2024.2343092","article-title":"A systematic review of the effect of semaglutide on lean mass: Insights from clinical trials","volume":"25","author":"Bikou","year":"2024","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4674","DOI":"10.1111\/dom.16541","article-title":"The effects of anti-obesity medications on bone metabolism: A critical appraisal","volume":"27","author":"Anastasilakis","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1785321","DOI":"10.1155\/2024\/1785321","article-title":"Effects of Glucagon-Like Peptide-1 Receptor Agonists on Bone Metabolism in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis","volume":"2024","author":"Li","year":"2024","journal-title":"Int. J. Endocrinol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: The STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"970733","DOI":"10.3389\/fendo.2022.970733","article-title":"Characteristics and possible mechanisms of metabolic disorder in overweight women with polycystic ovary syndrome","volume":"13","author":"Yu","year":"2022","journal-title":"Front. Endocrinol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"r1512","DOI":"10.1136\/bmj.r1512","article-title":"Malnutrition with use of GLP-1 agonists is an underestimated real world harm","volume":"390","author":"Fallows","year":"2025","journal-title":"BMJ"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Makizako, H. (2019). Frailty and Sarcopenia as a Geriatric Syndrome in Community-Dwelling Older Adults. Int. J. Environ. Res. Public Health, 16.","DOI":"10.3390\/ijerph16204013"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6818\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T10:30:25Z","timestamp":1788431425000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/17\/6818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":27,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["jcm15176818"],"URL":"https:\/\/doi.org\/10.3390\/jcm15176818","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}